353 related articles for article (PubMed ID: 34445596)
1. Hexosamine Biosynthetic Pathway-Derived O-GlcNAcylation Is Critical for RANKL-Mediated Osteoclast Differentiation.
Kim MJ; Kim HS; Lee S; Min KY; Choi WS; You JS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445596
[TBL] [Abstract][Full Text] [Related]
2. Hexosamine biosynthetic pathway promotes the antiviral activity of SAMHD1 by enhancing O-GlcNAc transferase-mediated protein O-GlcNAcylation.
Hu J; Gao Q; Yang Y; Xia J; Zhang W; Chen Y; Zhou Z; Chang L; Hu Y; Zhou H; Liang L; Li X; Long Q; Wang K; Huang A; Tang N
Theranostics; 2021; 11(2):805-823. PubMed ID: 33391506
[No Abstract] [Full Text] [Related]
3. HBP/O-GlcNAcylation Metabolic Axis Regulates Bone Resorption Outcome.
Taira TM; Ramos-Junior ES; Melo PH; Costa-Silva CC; Alteen MG; Vocadlo DJ; Dias WB; Cunha FQ; Alves-Filho JC; Søe K; Fukada SY
J Dent Res; 2023 Apr; 102(4):440-449. PubMed ID: 36749069
[TBL] [Abstract][Full Text] [Related]
4. Glucosamine Suppresses Osteoclast Differentiation through the Modulation of Glycosylation Including O-GlcNAcylation.
Takeuchi T; Sugimoto A; Imazato N; Tamura M; Nakatani S; Kobata K; Arata Y
Biol Pharm Bull; 2017; 40(3):352-356. PubMed ID: 28250278
[TBL] [Abstract][Full Text] [Related]
5. Single cell and bulk RNA expression analyses identify enhanced hexosamine biosynthetic pathway and O-GlcNAcylation in acute myeloid leukemia blasts and stem cells.
Schauner R; Cress J; Hong C; Wald D; Ramakrishnan P
Front Immunol; 2024; 15():1327405. PubMed ID: 38601153
[TBL] [Abstract][Full Text] [Related]
6. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.
Pham LV; Bryant JL; Mendez R; Chen J; Tamayo AT; Xu-Monette ZY; Young KH; Manyam GC; Yang D; Medeiros LJ; Ford RJ
Oncotarget; 2016 Dec; 7(49):80599-80611. PubMed ID: 27716624
[TBL] [Abstract][Full Text] [Related]
7. OGT-mediated O-GlcNAcylation promotes NF-κB activation and inflammation in acute pancreatitis.
Zhang D; Cai Y; Chen M; Gao L; Shen Y; Huang Z
Inflamm Res; 2015 Dec; 64(12):943-52. PubMed ID: 26407569
[TBL] [Abstract][Full Text] [Related]
8. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells.
Ma Z; Vocadlo DJ; Vosseller K
J Biol Chem; 2013 May; 288(21):15121-30. PubMed ID: 23592772
[TBL] [Abstract][Full Text] [Related]
9. Hexosamine biosynthetic pathway and
Kim DY; Park J; Han IO
Am J Physiol Cell Physiol; 2023 Oct; 325(4):C981-C998. PubMed ID: 37602414
[TBL] [Abstract][Full Text] [Related]
10. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
[TBL] [Abstract][Full Text] [Related]
11. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
12. Epithelial Mesenchymal Transition Induces Aberrant Glycosylation through Hexosamine Biosynthetic Pathway Activation.
Lucena MC; Carvalho-Cruz P; Donadio JL; Oliveira IA; de Queiroz RM; Marinho-Carvalho MM; Sola-Penna M; de Paula IF; Gondim KC; McComb ME; Costello CE; Whelan SA; Todeschini AR; Dias WB
J Biol Chem; 2016 Jun; 291(25):12917-29. PubMed ID: 27129262
[TBL] [Abstract][Full Text] [Related]
13. RNA-binding protein Musashi2 induced by RANKL is critical for osteoclast survival.
Fujiwara T; Zhou J; Ye S; Zhao H
Cell Death Dis; 2016 Jul; 7(7):e2300. PubMed ID: 27441652
[TBL] [Abstract][Full Text] [Related]
14. Cross-talk between two essential nutrient-sensitive enzymes: O-GlcNAc transferase (OGT) and AMP-activated protein kinase (AMPK).
Bullen JW; Balsbaugh JL; Chanda D; Shabanowitz J; Hunt DF; Neumann D; Hart GW
J Biol Chem; 2014 Apr; 289(15):10592-10606. PubMed ID: 24563466
[TBL] [Abstract][Full Text] [Related]
15. mTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer.
Sodi VL; Khaku S; Krutilina R; Schwab LP; Vocadlo DJ; Seagroves TN; Reginato MJ
Mol Cancer Res; 2015 May; 13(5):923-33. PubMed ID: 25636967
[TBL] [Abstract][Full Text] [Related]
16. O-GlcNAcylation Enhances Double-Strand Break Repair, Promotes Cancer Cell Proliferation, and Prevents Therapy-Induced Senescence in Irradiated Tumors.
Efimova EV; Appelbe OK; Ricco N; Lee SS; Liu Y; Wolfgeher DJ; Collins TN; Flor AC; Ramamurthy A; Warrington S; Bindokas VP; Kron SJ
Mol Cancer Res; 2019 Jun; 17(6):1338-1350. PubMed ID: 30885991
[TBL] [Abstract][Full Text] [Related]
17. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
18. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
19. On a sugar high: Role of O-GlcNAcylation in cancer.
Le Minh G; Esquea EM; Young RG; Huang J; Reginato MJ
J Biol Chem; 2023 Nov; 299(11):105344. PubMed ID: 37838167
[TBL] [Abstract][Full Text] [Related]
20. Cross regulation between mTOR signaling and O-GlcNAcylation.
Very N; Steenackers A; Dubuquoy C; Vermuse J; Dubuquoy L; Lefebvre T; El Yazidi-Belkoura I
J Bioenerg Biomembr; 2018 Jun; 50(3):213-222. PubMed ID: 29524020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
